Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03896256 · ClinicalTrials.gov registry record · Early Phase 1
Ketamine for Refractory Chronic Migraine: a Pilot Study
A Early Phase 1 study of Migraine Headache With Intractable Migraine, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT03896256: Completed Early Phase 1 study of Migraine Headache With Intractable Migraine, sponsored by Thomas Jefferson University.
NCT03896256 is a Early Phase 1 study of Migraine Headache With Intractable Migraine that has completed, run by Thomas Jefferson University. The registered enrollment target is 6 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03896256, a Early Phase 1 study of Migraine Headache With Intractable Migraine, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
Ketamine is a drug used for anesthesia but at low doses it is a very effective pain reliever in several chronic conditions. Preliminary studies have shown that ketamine might be effective for patients with refractory chronic migraine, which is a severe type of headache for which patients usually have tried and failed many medications and can cause severe disability to their lives. This study will evaluate ketamine prospectively when given to patients who have "failed" an initial inpatient treatment.
Primary Outcome
Each patient will serve as his or her own control.
Conditions Studied
Interventions
- DRUG ketamine infusion
Study Locations (1)
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-03-22 |
| Est. Completion | 2020-01-01 |
| Phase | Early Phase 1 |
What the finished NCT03896256 record still lists
NCT03896256 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Migraine Headache With Intractable Migraine appearing as the primary indexed condition, and to 1 intervention - of which ketamine infusion is the first listed.
NCT03896256 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03896256 about?
NCT03896256 is a clinical study titled "Ketamine for Refractory Chronic Migraine: a Pilot Study". Ketamine is a drug used for anesthesia but at low doses it is a very effective pain reliever in several chronic conditions. Preliminary studies have shown that ketamine might be effective for patients with refractory chronic migraine, which is a severe type of headache for which patients usually hav...
What is the current status of trial NCT03896256?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2019-03-22. Estimated completion is 2020-01-01.
What conditions does trial NCT03896256 study?
This clinical trial studies the following conditions: Migraine Headache With Intractable Migraine.
What interventions are being tested in trial NCT03896256?
The interventions under investigation include: ketamine infusion (DRUG).
Who is sponsoring clinical trial NCT03896256?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03896256 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03896256's enrollment target sits among peer trials
6 1846th of 2000 higher than 114 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI